QAI: Powered Microneedle Device
What it covers
A powered microneedle device is a device using one or more needles to mechanically puncture and injure skin tissue for aesthetic use.
FDA’s definition of product code QAI, from the Product Classification database.
Recent clearances
| 510(k) | Device | Applicant | Decision | Type |
|---|---|---|---|---|
| K252591 | Automatic Micro Needle System (CODE-X) | Woorhi Mechatronics Co., Ltd. | May 13, 2026 | Traditional |
| K253002 | SkinStylus SteriLock MicroSystem (MP1209SL) | Esthetic Medical, Inc. | Feb 19, 2026 | Traditional |
| K252752 | ellacor System with Micro-Coring Technology | Cytrellis Biosystems, Inc. | Oct 30, 2025 | Traditional |
| K253153 | SER Pen Carain MicroSystem (MP1209SP) | Su-Ko Technologies, LLC | Oct 29, 2025 | Special |
| K243800 | PRO Pen Microneedling System (6883) | Dermalogica, LLC | Aug 25, 2025 | Traditional |
| K243143 | E-PEN (E-PEN) | Bomtech Electronics Co., Ltd. | Apr 7, 2025 | Traditional |
| K243472 | 1NEED Pro | Campomats S.R.L. | Mar 19, 2025 | Traditional |
| K241790 | XCELLARISPRO TWIST microneedling device | Dermaroller GmbH | Mar 6, 2025 | Traditional |
| K241355 | SER Pen Carain MicroSystem (MP1209SP) | Su-Ko Technologies, LLC | Oct 9, 2024 | Traditional |
| K241400 | SkinPen Precision Elite System | Crown Aesthetics | Aug 29, 2024 | Traditional |
Clearances by year
26 QAI 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.
| Year | Clearances | Median days to decision |
|---|---|---|
| 2026 (so far) | 2 | 212 |
| 2025 | 6 | 160 |
| 2024 | 3 | 104 |
| 2023 | 2 | 141 |
| 2022 | 4 | 172 |
| 2021 | 4 | 226 |
| 2020 | 2 | 169 |
| 2019 | 1 | 318 |
| 2018 | 2 | 385 |
Who submits
18 applicants cleared a QAI device since 2011. 69% of the clearances went to applicants in United States, then Germany (15%), South Korea (8%) and China (4%). By type: Traditional 88%, Special 8% and Direct 4%.
| Applicant | Clearances since 2011 |
|---|---|
| Crown Aesthetics | 3 |
| Mt. Derm GmbH | 3 |
| Cytrellis Biosystems, Inc. | 2 |
| Eclipse Medcorp, LLC | 2 |
| Esthetic Medical, Inc. | 2 |
| Su-Ko Technologies, LLC | 2 |
| Bellus Medical, LLC | 1 |
| Bomtech Electronics Co., Ltd. | 1 |
How FDA classifies it
Class II (special controls). The special controls for this device are:
(1) The technical specifications and needle characteristics must be identified, including needle length, geometry, maximum penetration depth, and puncture rate.
(2) Non-clinical performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested:
(i) Accuracy of needle penetration depth and puncture rate;
(ii) Safety features built into the device to protect against cross-contamination, including fluid ingress protection; and
(iii) Identification of the maximum safe needle penetration depth for the device for the labeled indications for use.
(3) Performance data must demonstrate the sterility of the patient-contacting components of the device.
(4) Performance data must support the shelf life of the device by demonstrating continued sterility, package integrity, and device functionality over the intended shelf life.
(5) Performance data must demonstrate the electrical safety and electromagnetic compatibility (EMC) of all electrical components of the device.
(6) Software verification, validation, and hazard analysis must be performed for all software components of the device.
(7) The patient-contacting components of the device must be demonstrated to be biocompatible.
(8) Performance data must validate the cleaning and disinfection instructions for reusable components of the device.
(9) Labeling must include the following:
(i) Information on how to operate the device and its components and the typical course of treatment;
(ii) A summary of the device technical parameters, including needle length, needle geometry, maximum penetration depth, and puncture rate;
(iii) Validated methods and instructions for reprocessing of any reusable components;
(iv) Disposal instructions; and
(v) A shelf life.
(10) Patient labeling must be provided and must include:
(i) Information on how the device operates and the typical course of treatment;
(ii) The probable risks and benefits associated with use of the device; and
(iii) Postoperative care instructions.
From 21 CFR 878.4430. Special controls are the requirements a 510(k) must show it meets.
Standards
21 CFR 878.4430 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent QAI clearances declared.
Ask about QAI
Questions about QAI
What is FDA product code QAI?
Product code QAI, “Powered Microneedle Device” in FDA's classification database, is a Class II device type under 21 CFR 878.4430 (microneedling device for aesthetic use), reviewed by FDA's General, Plastic Surgery panel. FDA's 510(k) database lists 26 clearances under QAI, 26 of them since 2011.
How many 510(k) clearances are there under QAI?
FDA’s 510(k) database listed 26 clearances under QAI as of Oct 29, 2026, 26 of them decided since 2011; the most recent decision was May 13, 2026. The Predicate Finder searches the live database.
How long does FDA take to clear a QAI 510(k)?
For the 8 QAI clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 171 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.
Which companies have the most QAI clearances?
Since 2011: Crown Aesthetics (3), Mt. Derm GmbH (3), Cytrellis Biosystems, Inc. (2), Eclipse Medcorp, LLC (2) and Esthetic Medical, Inc. (2). 18 applicants have cleared a QAI device in that time.